Optimizing levodopa pharmacokinetics: Intestinal infusion versus oral sustained-release tablets

Clinical Neuropharmacology

Volumn 26, Issue 3, 2003, Pages 156-163

  Nyholm, Dag ^a,b   Askmark, Håkan ^a   Gomes Trolin, Cecilia ^a   Knutson, Tina ^a   Lennernäs, Hans ^a   Nyström, Christer ^a   Aquilonius, Sten Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Infusion; Levodopa; Parkinson's disease; Pharmacokinetics; Sustained release

Indexed keywords

3 O METHYLDOPA; ANTIPARKINSON AGENT; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DRUG METABOLITE; DUODOPA; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFUSION; DUODENUM; DYSKINESIA; FEMALE; FLUOROSCOPY; GEL; HUMAN; INFUSION PUMP; INTESTINE; MALE; MOTOR PERFORMANCE; NASODUODENAL TUBE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIDE EFFECT; SUSPENSION; SUSTAINED RELEASE PREPARATION; TABLET FORMULATION; TREATMENT OUTCOME; TUBE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DUODENUM; FEMALE; HUMANS; INFUSIONS, PARENTERAL; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 0038389152     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200305000-00010     Document Type: Article

References (25)

1. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55(suppl 1):1-9.
2. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000; 23:S109-15.
3. Tedroff J, Aquilonius SM, Hartvig P, et al. Cerebral uptake and utilization of therapeutic [beta-11C]-L-dopa in Parkinson's disease measured by positron emission tomography. Relations to motor response. Acta Neurol Scand 1992;85:95-102.
4. Tedroff J, Pedersen M, Aquilonius SM, et al. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology 1996;46:1430-6.
5. de la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298-303.
6. Nyholm D, Lennernas H, Gomes-Trolin C, et al. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 2002;25:89-96.
7. Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology 1988;38:419-21.
8. Cedarbaum JM, Kutt H, McDowell FH. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 1989;39:38-44.
9. Fagerholm U, Lindahl A, Lennernas H. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. J Pharm Pharmacol 1997;49:687-90.
10. Lennernas H, Nilsson D, Aquilonius SM, et al. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol 1993;35:243-50.
11. Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999; 51:593-628.
12. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in patients with Parkinson's disease. Neurology 1994;44:913-9.
13. Marsden CD. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa. Drugs 1998; 55(suppl 1):17-22.
14. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-6.
15. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in patients with Parkinson's disease. Neurology 1975;25:1144-8.
16. Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982;ii:412-5.
17. Kurlan R, Rubin AJ, Miller C, et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20:262-5.
18. Syed N, Murphy J, Zimmerman T Jr, et al. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998; 13:336-8.
19. Stocchi F, Ruggieri S, Brughitta G, et al. Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation. J Neural Transm Suppl 1986;22:209-18.
20. Nilsson D, Hansson LE, Johansson K, et al. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998;97:175-83.
21. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurol Scand 2001;104:343-8.
22. Johnels B, Ingvarsson PE, Thorselius M, et al. Disability profiles and objective quantitative assessment in Parkinson's disease. Acta Neurol Scand 1989;79:227-38.
23. Blandini F, Martignoni E, Pacchetti C, et al. Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 1997;700:278-82.
24. The Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001;345:956-63.
25. Nutt JG, Rufener SL, Carter JH, et al. Interactions between deep brain stimulation and levodopa in Parkinson's disease. Neurology 2001;57:1835-42.